- RecruitingPHASE3
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
This study is looking at a new medicine called INCB161734, given alongside standard chemotherapy, for advanced pancreatic cancer with a specific genetic change (KRAS G12D). It aims to see if this combination works better and is safe for people who haven't had treatment for their advanced cancer.
For: Solid TumorsUnited States · Australia · Austria - RecruitingPHASE1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
This study is looking at a new treatment called INCB161734 for advanced cancers with a specific genetic change (KRAS G12D mutation). Researchers want to see if it's safe and how well it works, either alone or with other cancer drugs.
For: Solid TumorsUnited States · Australia · Belgium